SUVN-502

· Suven Life Sciences Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SUVN-502, covering 2023-06-09 to 2023-06-09. Get the full timeline:

Most recent: Clinical Trial Update: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study [Phase 2]